{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Pfizer Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
Pfizer Inc. has recently achieved a Golden Cross, indicating a potential shift in market sentiment and increased investor confidence. Despite a challenging year, recent technical indicators show bullish trends, suggesting a possible turnaround. With a market capitalization of around $155.6 billion, Pfizer remains a key player in the pharmaceuticals sector.
Is Pfizer Inc. technically bullish or bearish?
As of October 10, 2025, Pfizer Inc. shows a mildly bullish technical trend supported by positive MACD indicators, but its significant underperformance compared to the S&P 500 raises caution.
Is Pfizer Inc. technically bullish or bearish?
As of October 10, 2025, Pfizer Inc. shows a mildly bullish technical trend, supported by positive MACD and moving averages, but has underperformed the S&P 500 significantly year-to-date and over the past year.
Pfizer Inc. Stock Hits Day Low Amid Price Pressure, Reaches $26.39
Pfizer Inc. saw a significant stock decline today, contrasting with a slight increase in the S&P 500. Despite recent positive trends and strong financial metrics, including high return on capital and net profit growth, the stock's year-to-date performance remains negative, reflecting challenges over the past three years.
Pfizer Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Pfizer Inc. has recently revised its market evaluation, with its stock currently priced at $26.43. The company has experienced significant volatility over the past year, with a high of $30.43 and a low of $20.91. Technical indicators show mixed signals, reflecting varied performance compared to the S&P 500.
Is Pfizer Inc. technically bullish or bearish?
As of October 3, 2025, Pfizer Inc. shows a mildly bullish technical trend with positive momentum indicators, despite some short-term bearish signals, and has outperformed the S&P 500 in recent weeks while still facing longer-term challenges.
Is Pfizer Inc. technically bullish or bearish?
As of October 3, 2025, Pfizer Inc. shows a mildly bullish trend with strong weekly indicators, despite some short-term bearish signals, having outperformed the S&P 500 in recent weeks.
Is Pfizer Inc. technically bullish or bearish?
As of October 3, 2025, Pfizer Inc. shows a mildly bullish trend supported by positive weekly and monthly MACD and KST indicators, despite daily moving averages indicating mild bearishness, while it has outperformed the S&P 500 in the short term but underperformed over the longer term.
Pfizer Inc. Hits Day High with 7.97% Surge in Stock Price
Pfizer Inc. saw a notable increase in stock performance on September 30, 2025, contrasting with the S&P 500's modest rise. Despite recent gains, the company has faced longer-term challenges. Financially, Pfizer shows strong management efficiency, positive quarterly results, and a high dividend yield, appealing to income-focused investors.
Is Pfizer Inc. technically bullish or bearish?
As of September 8, 2025, Pfizer Inc. is in a mildly bearish trend, with key indicators like a bearish daily moving average and underperformance compared to the S&P 500, showing a year-to-date return of -8.97% versus the S&P 500's 12.22%.
Is Pfizer Inc. overvalued or undervalued?
As of October 29, 2024, Pfizer Inc. is considered very attractive with a P/E ratio of 15 and a PEG ratio of 0.13, indicating it is undervalued compared to peers like Eli Lilly and Merck, despite underperforming the S&P 500 with a year-to-date return of -8.97%, while offering a strong dividend yield of 428.12% and a solid ROE of 16.06%.
Is Pfizer Inc. technically bullish or bearish?
As of May 29, 2025, the trend is mildly bearish due to daily moving averages and weekly Bollinger Bands indicating weakness, despite some mildly bullish signals from MACD and KST on longer time frames.
Is Pfizer Inc. overvalued or undervalued?
As of October 29, 2024, Pfizer Inc. is considered a very attractive investment due to its undervalued status with a P/E ratio of 15, a PEG ratio of 0.13, and a high dividend yield of 428.12%, especially when compared to peers like Eli Lilly and Johnson & Johnson, despite its recent underperformance against the S&P 500.
Who are in the management team of Pfizer Inc.?
As of March 2022, Pfizer Inc.'s management team includes Dr. Albert Bourla as Chairman and CEO, with Mr. Shantanu Narayen as Lead Independent Director and several Independent Directors: Dr. Susan Desmond-Hellmann, Mr. Ronald Blaylock, Mr. Joseph Echevarria, and Dr. Scott Gottlieb.
What does Pfizer Inc. do?
Pfizer Inc. is a global biopharmaceutical company focused on the discovery, development, and manufacture of healthcare products. As of March 2025, it reported net sales of $13.7 billion and a market cap of $230.4 billion.
How big is Pfizer Inc.?
As of Jun 18, Pfizer Inc. has a market capitalization of $230.43 billion, with net sales of $62.46 billion and a net profit of $7.90 billion over the latest four quarters. Shareholder's funds are $88.20 billion, and total assets amount to $213.40 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
